At the news
? BULLISHIMPACT 5/10 8-K filed Jul 20, 2026 at 07:13 ET
Armata Pharmaceuticals announced clinical, regulatory, and manufacturing progress for its lead candidate AP-SA02, including submission of the Phase 3 protocol to the FDA and completion of four engineering runs, keeping the Phase 3 superiority study on track for H2 2026. The company also disclosed a $2.5 million DoD award continuation (total $28.7M) and promoted David House to CFO. The clinical update is a positive catalyst but the company remains pre-revenue with no financial results reported.
- Phase 3 superiority protocol for AP-SA02 submitted to FDA; all End-of-Phase 2 meeting comments addressed.
- Four engineering runs of AP-SA02 completed; clinical trial material production is the next manufacturing step.
- Phase 3 study remains on track to initiate in the second half of 2026.
- DoD award continuation of $2.5 million brings total funding under the award to $28.7 million.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access